Premium Ostarine for Sale | ≥99% Purity | 48-Hour Delivery Across EU & UK

Ostarine (MK-2866): The Most Clinically Researched SARM for Muscle & Bone Studies

https://eupeptidelap.co.uk/ is proud to present Ostarine (MK-2866), a premium research-grade selective androgen receptor modulator (SARM) manufactured to the highest analytical standards. As a trusted peptide vendor uk and leading EU peptide supplier, we provide researchers across Europe with Ostarine for sale that delivers exceptional purity, consistency, and documented quality .

Ostarine (MK-2866) , also known by its chemical identifiers Enobosarm, GTx-024, or VERU-024, represents the most extensively studied SARM in clinical research, with data from multiple phase II and phase III trials involving over 968 older adults and patients with muscle-wasting conditions . This investigational compound was developed for the treatment of muscle wasting, osteoporosis, and cancer cachexia, and has demonstrated remarkable tissue-selective anabolic properties in both preclinical and clinical settings .

MK-2866 is a non-steroidal SARM designed to selectively bind to androgen receptors in skeletal muscle and bone tissue with a Ki of 3.8 nM . Unlike traditional anabolic steroids that affect androgen receptors throughout the body—leading to unwanted side effects in the prostate, skin, and other tissues—Ostarine is engineered to minimize androgenic activity while delivering muscle- and bone-building effects . At 10 nM concentration, Ostarine modulates AR transcriptional activity in CV-1 cells with 94-100% relative activity compared to DHT, confirming its potent and selective mechanism of action .

Our collaboration with certified GMP facilities ensures that every batch of Ostarine meets rigorous quality control specifications, making eupeptidelap.co.uk the preferred destination for researchers seeking to buy peptide online UK and across the European Union. The compound is supplied with comprehensive documentation, including Certificates of Analysis and batch-specific purity data .

For researchers seeking to buy peptide online EU for investigations into muscle preservation, bone density, metabolic regulation, or age-related sarcopenia, eupeptidelap.co.uk offers Ostarine (MK-2866) with guaranteed 48 hour delivery peptide service. Whether your laboratory is based in London, Berlin, Paris, or anywhere in the European Union, our rapid shipping ensures your research continues without interruption.

The Scientific Foundation of Ostarine (MK-2866)

Mechanism of Action: Selective Androgen Receptor Modulation

Ostarine (MK-2866) exerts its effects through highly selective binding to androgen receptors (AR), with a reported Ki of 3.8 nM and an ED50 of 0.44 mg/day . This high-affinity binding ensures potent activation of androgen receptor signaling pathways specifically in target tissues such as skeletal muscle and bone .

The key innovation of SARMs like Ostarine lies in their tissue selectivity. Upon oral administration, MK-2866 acts as an agonist in anabolic tissues while minimizing androgenic effects in the prostate and skin . Lack of PSA increases in men and hair growth in women further corroborated the selective anabolic effects of Ostarine in clinical studies .

When Ostarine binds to androgen receptors in muscle and bone tissue, it triggers a cascade of anabolic effects:

Enhanced Protein Synthesis: Boosts the production of new muscle proteins, supporting hypertrophy and maintenance
Reduced Protein Breakdown: Limits the activity of pathways active in muscle atrophy, such as the ubiquitin-proteasome system
Promotion of Satellite Cell Activity: Encourages satellite cells (muscle stem cells) to proliferate and repair damaged muscle fibers
Preservation of Bone Density: Androgen receptor activation supports bone health through increased osteoblast activity and reduced osteoclast-mediated resorption

Key Research Applications

Muscle Preservation and Sarcopenia Research: Ostarine (MK-2866) is extensively used in studies of age-related muscle loss. Clinical studies demonstrate that Enobosarm at clinically tested doses (1–3 mg daily) produces statistically significant improvements in lean muscle mass compared to placebo . Elderly participants and patients with muscle wasting have shown average gains of 1–1.5 kg in lean body mass over 12–24 weeks . Improvements in walking speed and stair climbing power have been reported, with gains most pronounced in those with baseline muscle weakness or wasting . Researchers investigating muscle-wasting conditions, cachexia, and sarcopenia rely on Ostarine to probe androgen receptor-mediated pathways in skeletal muscle .

Bone Density and Osteoporosis Research: Ostarine has demonstrated significant positive effects on bone tissue in multiple preclinical studies. A comprehensive study using orchiectomized rats as a model of male osteoporosis evaluated various regimens of enobosarm and compared them to testosterone treatment . Key findings include:

Bone Healing Improvement: Both enobosarm and testosterone increased bone healing in orchiectomized rats
Cortical Bone Effects: Enobosarm treatment led to increased cortical bone thickness in some groups
Biomechanical Properties: Improved yield load and stiffness parameters in treated animals
Levator Ani Muscle Weight: Enobosarm therapy (th) significantly increased levator ani weight compared to untreated Orx rats (0.57g vs. 0.31g), confirming anabolic activity

These findings make MK-2866 valuable for osteoporosis research, fracture healing studies, and investigations into age-related bone loss .

Cancer Cachexia and Muscle Wasting: Enobosarm has been studied in cancer cachexia patients, where it increased lean body mass compared to placebo in patients with cancer-induced muscle wasting . A phase II randomized controlled trial found that Enobosarm increased lean body mass compared to placebo, although strength outcomes varied and long-term effects remain unclear . Researchers investigating chronic disease-related muscle loss utilize Ostarine to understand mechanisms of muscle preservation in catabolic states .

Metabolic Research and Body Composition: Ostarine has been shown to produce dose-dependent increases in muscle mass with significant reductions in fat mass . Recent clinical developments have highlighted Ostarine’s potential in metabolic research. Veru Pharmaceuticals has announced plans to initiate a Phase 2 obesity trial for Enobosarm in combination with GLP-1 receptor agonists . The rationale is that Ostarine could potentially augment fat reduction and total weight loss while preserving muscle mass—a critical consideration in obesity treatment where rapid weight loss often leads to undesirable muscle wasting .

The totality of clinical data from five previous clinical trials demonstrates that enobosarm treatment leads to dose-dependent increases in muscle mass with improvements in physical function as well as significant dose-dependent reductions in fat mass . This dual effect makes it uniquely valuable for researchers investigating body composition, metabolic health, and the interface between muscle and adipose tissue.

Physical Function and Frailty Studies: Improvements in physical function metrics have been reported in elderly populations treated with Ostarine . These include increased walking speed and stair climbing power, making the compound relevant for studies on physical function, frailty, and rehabilitation in aging populations.

Quality Assurance: Setting the Standard for Research Compounds

Manufacturing Excellence

eupeptidelap.co.uk sources Ostarine (MK-2866) from certified facilities with rigorous quality control protocols:

HPLC Purity Analysis: ≥99% purity confirmed by high-performance liquid chromatography
Mass Spectrometry Verification: Molecular weight confirmation (389.33 g/mol) via LC-MS
Batch-Specific Certificates of Analysis: Complete documentation for each production run
Heavy Metal Testing: Ensures absence of contaminants
Microbiological Testing: Confirms absence of microbial contamination

Chemical and Product Specifications

Specification	Detail
Product Name	Ostarine (MK-2866, Enobosarm, GTx-024)
CAS Number	841205-47-8
Molecular Formula	C₁₉H₁₄F₃N₃O₃
Molecular Weight	389.33 g/mol
IUPAC Name	(2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
Binding Affinity	Ki = 3.8 nM
ED50	0.44 mg/day
Purity	≥99% (HPLC validated)
Appearance	White to off-white crystalline powder
Solubility	DMSO: 73 mg/mL (187.5 mM); Ethanol: 73 mg/mL (187.5 mM); Water: Insoluble
Storage (Powder)	-20°C: up to 36 months ; Protect from light, keep desiccated
Storage (In solvent)	-20°C: up to 3 months; -80°C: up to 6 months
Shipping	Ice packs + insulated packaging
Intended Use	Research and laboratory use only
Documentation	Certificate of Analysis provided with each batch

Stability and Handling

Ostarine (MK-2866) demonstrates excellent stability when stored properly:

Shelf Life: Up to 36 months when stored at -20°C in lyophilized form
Light Sensitivity: Store in original container, protected from direct light, argon charged recommended
Moisture Protection: Keep container tightly sealed, keep desiccated
Reconstituted Solutions: If preparing solutions for research, use within 3 months at -20°C or 6 months at -80°C; aliquot to avoid multiple freeze/thaw cycles
Transportation: Shipped in ice chest + ice packs to maintain stability during transit

Real-World Research Applications and Investigator Experiences

Clinical Trial Evidence

Ostarine (MK-2866) has been studied in multiple clinical trials involving over 968 older normal men, postmenopausal women, and patients with cancer-induced muscle wasting . Key findings from these studies include:

Phase II Study in Elderly Adults: A randomized, double-blind, placebo-controlled phase II study demonstrated that oral Enobosarm (MK-2866) significantly increased total lean body mass and improved physical function in healthy elderly men and postmenopausal women over 12 weeks
Cancer Cachexia Patients: A phase II randomized controlled trial found that Enobosarm increased lean body mass compared to placebo in patients with cancer-induced muscle wasting, although strength outcomes varied and long-term effects remain unclear
Systematic Review: A systematic review of randomized controlled trials on SARMs (including Enobosarm/MK-2866) found consistent lean mass increases in adults and identified safety considerations such as changes in liver enzymes

Bone Healing Studies

The effects of Ostarine on bone tissue have been rigorously evaluated in preclinical models. In a comprehensive study using orchiectomized rats as a model of male osteoporosis, enobosarm treatment demonstrated significant positive effects :

Levator Ani Muscle Weight: EN-th group: 0.57g vs. Orx control: 0.31g (p < 0.05)
Prostate Weight: EN-pr group: 0.62g vs. Orx control: 0.18g (p < 0.05) – indicating some androgenic activity at prophylactic doses
Cortical Bone Thickness: Dorsal cortical width increased in T-th (0.67mm) and T-pr (0.64mm) groups compared to Orx control (0.49mm)

These findings suggest that Ostarine could be further investigated for bone healing applications, though researchers should note the dose-dependent effects on prostate tissue observed in long-term studies .

Safety Profile in Research Settings

Clinical studies have established that Ostarine has a favorable pharmacokinetic profile with predictable absorption and elimination . When used in appropriate doses for research, reported observations include:

Mild, transient effects: Most common is mild elevations in liver enzymes (ALT and AST), which are reversible
Lipid changes: Decreases in HDL cholesterol that may pose cardiovascular risk with long-term use
Hormonal effects: Suppression of natural testosterone, usually modest and reversible
No significant prostate or hair-related side effects at tested doses in clinical trials
Rhabdomyolysis risk: A case report documented severe rhabdomyolysis (CPK up to 86,435 UI/L) and cytolysis (ALT up to 922 UI/L, AST up to 2558 UI/L) in an individual using a combination of cardarine and ostarine, highlighting the importance of appropriate dosing and monitoring

All research involving Ostarine (MK-2866) must be conducted with appropriate safety protocols and institutional oversight. Ostarine is not currently approved by regulatory bodies for any therapeutic indication; all use outside of clinical trials is considered experimental and should be conducted with appropriate monitoring .

Key Benefits

Most Clinically Researched SARM: Extensive data from multiple phase II/III trials involving over 968 subjects
≥99% HPLC Purity: Guaranteed purity for reliable, reproducible research results
Selective Androgen Receptor Modulation: High-affinity binding with Ki of 3.8 nM and ED50 of 0.44 mg/day
Tissue-Selective Activity: Anabolic effects in muscle and bone with minimized androgenic effects in prostate and skin
Muscle Preservation: Increases lean body mass by 1-1.5 kg over 12-24 weeks in clinical studies
Bone Anabolic Effects: Improves bone healing parameters in preclinical osteoporosis models
Physical Function Improvement: Increases walking speed and stair climbing power in elderly populations
Fat Mass Reduction: Significant dose-dependent reductions in fat mass in clinical studies
Cancer Cachexia Research: Proven efficacy in cancer-induced muscle wasting models
Obesity Research Applications: Being investigated in combination with GLP-1 agonists for weight loss
Osteoporosis Research: Well-documented in orchiectomized rat models
Fracture Healing Studies: Positive effects on bone biomechanics and cortical thickness
Oral Bioavailability: Excellent absorption for convenient administration
Well-Characterized Safety Profile: Extensive clinical data on adverse effects and monitoring parameters
Comprehensive Documentation: Batch-specific Certificates of Analysis included
Temperature-Controlled Packaging: Ice packs + insulated containers maintain compound integrity during transit
48-Hour EU & UK Delivery: Rapid shipping to research facilities across Europe
Batch Consistency: Rigorous quality control ensures lot-to-lot reproducibility
Expert Technical Support: Knowledgeable staff for formulation and protocol guidance
Competitive Pricing: Premium quality at accessible research budgets
EU Sourced: Manufactured and distributed from within the European Union
Research-Grade Material: Not for human consumption, for laboratory use only

Frequently Asked Questions

Q: Is Ostarine (MK-2866) suitable for human consumption?

A: No. Ostarine (MK-2866) from eupeptidelap.co.uk is strictly for research and laboratory use only . It is not for human or animal consumption. While Ostarine has been studied extensively in clinical trials, research-grade material is intended for investigational purposes only . Ostarine is not approved by regulatory bodies like the FDA, EMA, or MHRA for any therapeutic indication; all use outside of clinical trials is considered experimental . Researchers must handle this compound in accordance with institutional safety guidelines and local regulations.

Q: What purity level can I expect when I buy Ostarine from eupeptidelap.co.uk?

A: All Ostarine (MK-2866) from eupeptidelap.co.uk is tested to ≥99% purity by HPLC . Each batch is individually analyzed, and Certificates of Analysis are provided with every order, ensuring you receive material suitable for rigorous research applications.

Q: How should I store Ostarine for long-term stability?

A: Store Ostarine (MK-2866) powder at -20°C, protected from light and moisture, in a desiccated environment . Under these conditions, the powder remains stable for up to 36 months . For research requiring reconstituted solutions, prepare in DMSO and store at -80°C for up to 6 months or -20°C for up to 3 months, aliquoting to avoid repeated freeze-thaw cycles .

Q: What is the solubility of Ostarine for in vitro studies?

A: Ostarine (MK-2866) is highly soluble in DMSO (73 mg/mL; 187.5 mM) and ethanol (73 mg/mL; 187.5 mM) . It is insoluble in water . For cell culture applications, prepare a concentrated stock in DMSO, then dilute to working concentrations in culture medium. Final solvent concentrations should typically not exceed 0.1% in cell-based assays.

Q: What are the reported adverse effects of Ostarine in clinical studies?

A: Clinical studies have reported several side effects including mild elevations in liver enzymes (ALT and AST), which are typically reversible; decreases in HDL cholesterol that may pose cardiovascular risk with long-term use; and suppression of natural testosterone, usually modest and reversible . A case report documented severe rhabdomyolysis (CPK up to 86,435 UI/L) and cytolysis (ALT up to 922 UI/L) in an individual using a combination of cardarine and ostarine, highlighting the importance of appropriate dosing and monitoring .

Q: Do you ship Ostarine to EU countries?

A: Yes. As a dedicated EU peptide supplier, we ship Ostarine (MK-2866) to all European Union member states with our guaranteed 48 hour delivery peptide service. Our EU fulfilment centre ensures rapid delivery without customs delays. All shipments use ice packs and insulated packaging to maintain compound stability during transit .

Q: What documentation do you provide with Ostarine orders?

A: Every order includes a Certificate of Analysis with batch-specific purity data . Additional documentation, including HPLC chromatograms and mass spectrometry data, is available upon request for researchers requiring comprehensive analytical verification.

Q: What research areas commonly use Ostarine (MK-2866)?

A: Ostarine (MK-2866) is widely used in muscle preservation and sarcopenia research , bone density and osteoporosis studies , cancer cachexia investigations , metabolic research and obesity studies , physical function and frailty research , and fracture healing investigations .

Q: Has Ostarine been studied in clinical trials?

A: Yes, Ostarine (Enobosarm) has been studied in multiple clinical trials involving over 968 older normal men, postmenopausal women, and patients with cancer-induced muscle wasting . Phase 3 trials have been conducted in breast cancer, and Phase 2 trials in muscular atrophy, obesity, and overweight . Recent trials are exploring its use in obesity in combination with GLP-1 agonists .

Q: What is the mechanism of action of Ostarine?

A: Ostarine (MK-2866) is a selective androgen receptor modulator (SARM) that binds to androgen receptors with high affinity (Ki = 3.8 nM) . It works by selectively activating androgen receptors in muscle and bone tissue, promoting protein synthesis, reducing protein breakdown, and supporting bone formation while minimizing effects on tissues like the prostate . At 10 nM concentration, Ostarine modulates AR transcriptional activity with 94-100% relative activity compared to DHT .

Q: How does Ostarine compare to other SARMs for muscle research?

A: Ostarine is considered one of the most researched SARMs, known for its potential to preserve muscle mass during periods of calorie deficit and its ability to aid in muscle gain . Unlike more potent SARMs like RAD140 or LGD4033, Ostarine is often preferred for studies involving muscle preservation rather than aggressive mass building, with a comparatively milder side effect profile .

Q: Does Ostarine affect bone tissue?

A: Yes. Research demonstrates that Ostarine has significant positive effects on bone, including improved bone healing parameters in animal models of osteoporosis . Studies in orchiectomized rats showed beneficial effects on cortical bone thickness and biomechanical properties, suggesting potential applications in fracture healing and osteoporosis research .

Q: What is the legal status of Ostarine in the UK and EU?

A: Ostarine is not approved for medical use by regulatory bodies in the UK or EU . It is classified as an investigational drug and is not intended for human consumption. For research purposes, Ostarine is legally sold as a research chemical, but researchers should ensure compliance with all applicable institutional and legal frameworks .

Q: Do you offer bulk quantities of Ostarine for institutional research?

A: Yes. We accommodate bulk orders for research institutions. Contact our team at sales@eupeptidelap.co.uk for volume pricing, custom requirements, and supply agreements for ongoing research programs.

Q: Can Ostarine be used in cell culture studies?

A: Yes, Ostarine is suitable for cell culture research. Studies have shown that at 10 nM concentration, Ostarine modulates AR transcriptional activity in CV-1 cells cotransfected with human AR expression vector . Dissolve in DMSO (up to 73 mg/mL) and dilute to working concentrations in culture medium. Filter sterilize if required by your protocol.

Advance Your Research with Ostarine (MK-2866)

eupeptidelap.co.uk is your trusted source for Ostarine (MK-2866) , the premium choice for researchers investigating androgen receptor biology, muscle preservation, bone metabolism, and metabolic regulation. With over a decade of clinical research supporting its tissue-selective anabolic properties and involvement in multiple phase II/III trials, Ostarine represents the most extensively studied SARM in the research community . ...........................................

Whether you are exploring muscle preservation in aging populations, designing osteoporosis studies, investigating cancer cachexia, or studying metabolic regulation in obesity, our rigorously tested compound provides the quality and consistency your work demands. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Order today and experience the eupeptidelap.co.uk difference – premium quality, rapid 48-hour delivery across the EU and UK, and expert support for the European research community.

....... .. .. google

life sciences research

Cellular Recovery Processes Research Stack

CJC 1295 no DAC 5mg

CJC 1295 with DAC 5mg

CJC-1295 (no DAC), Ipamorelin 10mg (Blend)

GHRP-2 10mg + Mod GRF 1-29 10mg

Glow 70mg (R&D Only)

Ostarine – MK2866